NO20050701L - 4-pyrrolidino-fenyl-benzyleter derivater - Google Patents

4-pyrrolidino-fenyl-benzyleter derivater

Info

Publication number
NO20050701L
NO20050701L NO20050701A NO20050701A NO20050701L NO 20050701 L NO20050701 L NO 20050701L NO 20050701 A NO20050701 A NO 20050701A NO 20050701 A NO20050701 A NO 20050701A NO 20050701 L NO20050701 L NO 20050701L
Authority
NO
Norway
Prior art keywords
pyrrolidino
phenyl
benzyl ether
ether derivatives
derivatives
Prior art date
Application number
NO20050701A
Other languages
English (en)
Inventor
Wolfgang Wostl
Rosa Maria Rodriguez Sarmiento
Andrew William Thomas
Rene Wyler
Synese Jolidon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20050701L publication Critical patent/NO20050701L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Racemisk eller enantiomert rene 4-pyrrolidino derivater med formel (I), prosesser for deres fremstilling, farmasytiske preparater omfattende nevnte derivater og anvendelse av disse i forebygging og behandling av sykdom, f.eks. som slike som blir mediert av monoamin oksydase B inhibitorer, spesielt Alzheimers sykdom eller senil demens.
NO20050701A 2002-09-20 2005-02-09 4-pyrrolidino-fenyl-benzyleter derivater NO20050701L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20
PCT/EP2003/010383 WO2004026826A1 (en) 2002-09-20 2003-09-18 4-pyrrolidino-phenyl-benzyl ether derivatives

Publications (1)

Publication Number Publication Date
NO20050701L true NO20050701L (no) 2005-03-02

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20050665A NO330012B1 (no) 2002-09-20 2005-02-08 Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom
NO20050652A NO329754B1 (no) 2002-09-20 2005-02-08 Pyrrolidonderivater , farmasoytiske preparater inneholdende slike, slike forbindelserfor behandling av sykdommer samt anvendelse av medikamenter for behandling av skdom
NO20050701A NO20050701L (no) 2002-09-20 2005-02-09 4-pyrrolidino-fenyl-benzyleter derivater

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20050665A NO330012B1 (no) 2002-09-20 2005-02-08 Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom
NO20050652A NO329754B1 (no) 2002-09-20 2005-02-08 Pyrrolidonderivater , farmasoytiske preparater inneholdende slike, slike forbindelserfor behandling av sykdommer samt anvendelse av medikamenter for behandling av skdom

Country Status (31)

Country Link
US (4) US7151111B2 (no)
EP (3) EP1542971A1 (no)
JP (3) JP4335142B2 (no)
KR (3) KR100676015B1 (no)
CN (3) CN100503562C (no)
AR (3) AR041298A1 (no)
AT (2) ATE459601T1 (no)
AU (3) AU2003273901B2 (no)
BR (4) BRPI0314631B1 (no)
CA (3) CA2498335A1 (no)
CY (1) CY1110745T1 (no)
DE (2) DE60331559D1 (no)
DK (1) DK1542970T3 (no)
ES (2) ES2338646T3 (no)
GT (3) GT200300205A (no)
HR (3) HRP20050262A2 (no)
JO (2) JO2605B1 (no)
MX (3) MXPA05002880A (no)
MY (3) MY134480A (no)
NO (3) NO330012B1 (no)
NZ (3) NZ538046A (no)
PA (3) PA8583001A1 (no)
PE (3) PE20050077A1 (no)
PL (3) PL376019A1 (no)
PT (1) PT1542970E (no)
RU (3) RU2336268C2 (no)
SI (1) SI1542970T1 (no)
TW (3) TWI286132B (no)
UY (3) UY27990A1 (no)
WO (3) WO2004026826A1 (no)
ZA (3) ZA200501137B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8583001A1 (es) * 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
AU2005268894B2 (en) * 2004-08-02 2010-12-16 F. Hoffmann-La Roche Ag Benzyloxy derivatives as MAOB inhibitors
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
CN101142181B (zh) * 2005-03-15 2011-05-04 弗·哈夫曼-拉罗切有限公司 对映异构纯的4-吡咯烷子基苯基苄基醚衍生物的制备方法
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
EP2171478A4 (en) * 2007-03-30 2013-01-30 Univ California IN VIVO IMAGING METHOD FOR SULPHOTRANSFERASES
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
NZ711598A (en) 2013-03-14 2016-09-30 Dart Neuroscience Cayman Ltd Substituted naphthyridine and quinoline compounds as mao inhibitors
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
WO2015063001A1 (en) 2013-10-29 2015-05-07 F. Hoffmann-La Roche Ag Crystalline forms of a pyrrolidone derivative useful in the treatment of alzheimer's disease and preparation thereof
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
WO2016156124A1 (en) 2015-03-27 2016-10-06 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising sembragiline
EP3689870B1 (en) 2017-09-27 2022-07-13 Kagoshima University Analgesic drug using pac1 receptor antagonistic drug
EP3691634A4 (en) 2017-10-05 2021-03-31 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
CA3092747A1 (en) * 2018-03-08 2019-09-12 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
WO2020175134A1 (ja) 2019-02-27 2020-09-03 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痒薬
WO2021225161A1 (ja) 2020-05-08 2021-11-11 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
DK0393607T3 (da) 1989-04-19 1996-03-18 Otsuka Pharma Co Ltd Phenylcarboxylsyrederivater med en heteroring
NZ291508A (en) * 1994-08-30 1999-07-29 Sankyo Co Isoxazoles; preparation and medicaments
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
CA2244253C (en) 1996-03-15 2002-11-12 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
EP1165546A2 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
CN1222254C (zh) * 2000-02-10 2005-10-12 波滕西亚医疗公司 用无线能量源进行尿失禁治疗
EP1255513B1 (en) * 2000-02-14 2005-05-25 Potencia Medical AG Penile prosthesis
PA8583001A1 (es) * 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism

Also Published As

Publication number Publication date
KR100681586B1 (ko) 2007-02-09
DK1542970T3 (da) 2010-08-02
PL376019A1 (en) 2005-12-12
AR041297A1 (es) 2005-05-11
EP1542969A1 (en) 2005-06-22
CN1681779A (zh) 2005-10-12
GT200300204A (es) 2004-04-29
HK1083498A1 (zh) 2006-07-07
PE20050077A1 (es) 2005-03-01
NZ538046A (en) 2007-08-31
TWI286132B (en) 2007-09-01
KR20050057456A (ko) 2005-06-16
JO2604B1 (en) 2011-11-01
CA2498785C (en) 2011-07-26
RU2005111968A (ru) 2006-11-10
MY133332A (en) 2007-11-30
JO2605B1 (en) 2011-11-01
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
CN100383118C (zh) 2008-04-23
CA2496756A1 (en) 2004-04-01
BR0314299A (pt) 2005-12-13
HRP20050263A2 (en) 2006-12-31
GT200300206A (es) 2004-04-29
CA2496756C (en) 2012-01-10
AU2003267381A1 (en) 2004-04-08
UY27993A1 (es) 2004-03-31
US7151111B2 (en) 2006-12-19
JP2006503834A (ja) 2006-02-02
MY135696A (en) 2008-06-30
AU2003270213A1 (en) 2004-04-08
US20040106650A1 (en) 2004-06-03
PA8583501A1 (es) 2004-04-23
HK1084383A1 (en) 2006-07-28
ES2338646T3 (es) 2010-05-11
ATE459601T1 (de) 2010-03-15
AU2003273901A1 (en) 2004-04-08
EP1542971A1 (en) 2005-06-22
HK1083499A1 (zh) 2006-07-07
US20040116707A1 (en) 2004-06-17
BR0314314A (pt) 2005-07-26
HRP20050263B1 (hr) 2013-09-30
SI1542970T1 (sl) 2010-08-31
PE20050079A1 (es) 2005-03-01
NO330012B1 (no) 2011-02-07
BR0314631A (pt) 2005-08-02
EP1542970B1 (en) 2010-06-30
TW200413350A (en) 2004-08-01
CN100400509C (zh) 2008-07-09
JP2006503833A (ja) 2006-02-02
CY1110745T1 (el) 2015-06-10
NO329754B1 (no) 2010-12-13
ZA200501557B (en) 2005-09-08
HRP20050262A2 (en) 2006-06-30
AU2003273901B2 (en) 2008-07-10
PA8583601A1 (es) 2004-09-16
US20040097578A1 (en) 2004-05-20
DE60333202D1 (de) 2010-08-12
AR041298A1 (es) 2005-05-11
US7122562B2 (en) 2006-10-17
BRPI0314631B1 (pt) 2018-04-17
US7235581B2 (en) 2007-06-26
KR20050057466A (ko) 2005-06-16
JP4335142B2 (ja) 2009-09-30
RU2005111969A (ru) 2006-01-20
KR100676014B1 (ko) 2007-01-30
DE60331559D1 (de) 2010-04-15
MY134480A (en) 2007-12-31
PE20050078A1 (es) 2005-02-28
US20060122235A1 (en) 2006-06-08
WO2004026826A1 (en) 2004-04-01
ZA200501137B (en) 2006-12-27
GT200300205A (es) 2004-04-29
NZ538048A (en) 2007-05-31
TW200408624A (en) 2004-06-01
RU2323209C2 (ru) 2008-04-27
WO2004026825A1 (en) 2004-04-01
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
JP4335140B2 (ja) 2009-09-30
PL376021A1 (en) 2005-12-12
RU2336267C2 (ru) 2008-10-20
ZA200501311B (en) 2006-10-25
HRP20050261A2 (en) 2006-05-31
PL376018A1 (en) 2005-12-12
CA2498785A1 (en) 2004-04-01
RU2336268C2 (ru) 2008-10-20
CA2498335A1 (en) 2004-04-01
AU2003270213B8 (en) 2009-03-05
WO2004026827A1 (en) 2004-04-01
NO20050665L (no) 2005-04-18
PA8583001A1 (es) 2004-04-23
MXPA05002880A (es) 2005-05-27
MXPA05002878A (es) 2005-05-27
JP4335141B2 (ja) 2009-09-30
NZ538049A (en) 2007-05-31
CN100503562C (zh) 2009-06-24
RU2005111974A (ru) 2006-01-20
TWI331994B (en) 2010-10-21
US7037935B2 (en) 2006-05-02
JP2006510596A (ja) 2006-03-30
AU2003270213B2 (en) 2009-02-12
TWI337604B (en) 2011-02-21
UY27991A1 (es) 2004-03-31
CN1681777A (zh) 2005-10-12
NO20050652L (no) 2005-03-08
UY27990A1 (es) 2004-03-31
CN1681778A (zh) 2005-10-12
AR041299A1 (es) 2005-05-11
AU2003267381B2 (en) 2009-08-27
ES2344557T3 (es) 2010-08-31
PT1542970E (pt) 2010-07-19
KR100676015B1 (ko) 2007-01-30
ATE472530T1 (de) 2010-07-15
TW200410935A (en) 2004-07-01
KR20050057450A (ko) 2005-06-16

Similar Documents

Publication Publication Date Title
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20045281L (no) Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer
NO20050828L (no) lndol-3-svovelderivater
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
NO20064584L (no) Tetrahydropyridoindolderivater
NO20050290L (no) Nye tetrahydropyridin-derivater som renin-inhibitorer
NO20050514L (no) Sammensetning og antiviral aktivitet til substituerte azaindoloksoeddikpiperazinderivater
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
NO20063137L (no) Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
NO20055624L (no) Tropanderivater og deres anvendelse som Ace-inhibitorer
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
NO20062700L (no) Morfolinderivater som norepinefrin reopptaksinhibitorer
NO20061290L (no) Nye forbindelser
ATE305305T1 (de) Verwendung einer kombination von nicotinsäuren oder deren derivaten und riboflavin zur herstellung eines arzneimittels zur behandlung von primären kopfschmerzen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application